固态肿瘤治疗市场规模、份额、成长分析（按治疗类型、癌症适应症、最终用户和地区）—2025 年至 2032 年产业预测

全球固态肿瘤治疗市场预计将在 2023 年达到 1,770.6 亿美元，从 2024 年的 1915.8 亿美元成长到 2032 年的 3,598.9 亿美元，在预测期内（2025-2032 年）的复合年增长率达到 8.20%。

由于人口老化和生活方式改变导致癌症风险因素增加，乳癌、肺癌、大肠癌和摄护腺癌等癌症病例不断增加，全球固态肿瘤治疗市场正在扩大。对有效治疗方法的需求推动着标靶治疗和免疫疗法等先进治疗方法作为传统化疗的替代方案的应用。越来越多的癌症治疗方法，加上监管机构对新型疗法的稳定核准，进一步推动了市场成长。透过生物标记和基因组分析增加对个人化医疗的研发投资也值得注意。医疗支出增加、新兴经济体医疗可近性的改善以及对基于价值的照护的关注等因素，正在推动全球采用创新固体癌疗法。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 顾客购买行为分析

固态肿瘤药物市场规模（依治疗类型和复合年增长率） (2025-2032)

• 市场概览
• 化疗
• 标靶治疗
• 免疫疗法
• 荷尔蒙疗法
• 其他的

固态肿瘤药物市场规模（依癌症适应症和复合年增长率） (2025-2032)

• 市场概览
• 乳癌
• 肺癌
• 大肠直肠癌
• 摄护腺癌
• 肝癌
• 其他的

固态肿瘤药物市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 癌症研究中心
• 专科诊所

固态肿瘤药物市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Roche Holding AG（Switzerland）
• Novartis AG（Switzerland）
• AstraZeneca plc（United Kingdom）
• Bristol Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• AbbVie Inc.（USA）
• Sanofi SA（France）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Gritstone Bio, Inc.（USA）
• Black Diamond Therapeutics, Inc.（USA）

结论和建议

Global Solid Tumor Therapeutics Market size was valued at USD 177.06 Billion in 2023 and is poised to grow from USD 191.58 Billion in 2024 to USD 359.89 Billion by 2032, growing at a CAGR of 8.20% in the forecast period (2025-2032).

The global solid tumor therapeutics market is expanding due to a rise in cancer cases like breast, lung, colorectal, and prostate cancers, fueled by aging populations and lifestyle changes that increase cancer risk factors. The demand for effective therapies is prompting the adoption of advanced treatment options, including targeted therapies and immunotherapies, as alternatives to traditional chemotherapy. An influx of regulatory approvals for new therapies and a robust oncology drug pipeline are further stimulating market growth. Increased investment in R&D for personalized medicine, driven by biomarkers and genomic profiling, is also noteworthy. Contributing factors such as rising healthcare spending, improved access in emerging economies, and the focus on value-based care are facilitating greater adoption of innovative solid tumor therapies worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Solid Tumor Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Solid Tumor Therapeutics Market Segments Analysis

The global solid tumour therapeutics market is segmented based on therapy type, cancer indication, end user, and region. In terms of therapy type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. Based on cancer indication, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, and others. Based on end user, the market is segmented into hospitals, cancer research centers, and specialty clinics. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Solid Tumor Therapeutics Market

One of the key market drivers for the global solid tumor therapeutics market is the increasing prevalence of solid tumors due to rising risk factors such as aging populations, unhealthy lifestyle choices, and environmental influences. As the incidence of various solid tumors, including breast, lung, and colorectal cancers, continues to escalate, there is a growing demand for effective therapeutic options. Additionally, advancements in cancer research and technology have facilitated the development of targeted therapies and immunotherapies, providing more effective treatment modalities. This convergence of rising patient needs and innovative treatment approaches is significantly propelling market growth.

Restraints in the Global Solid Tumor Therapeutics Market

One significant market restraint for the global solid tumor therapeutics market is the high cost associated with the development and commercialization of innovative treatments. The complex nature of solid tumors often necessitates extensive research and clinical trials, which can lead to substantial financial investments. This economic burden can limit access for patients, particularly in developing regions, and may deter both pharmaceutical companies and investors from pursuing new therapies. Additionally, stringent regulatory requirements can further complicate the approval process, causing delays and increasing overall development costs, thereby hindering the growth potential of the market.

Market Trends of the Global Solid Tumor Therapeutics Market

The global solid tumor therapeutics market is witnessing a significant trend towards the integration of AI and digital pathology for enhanced treatment personalization. These technological advancements are revolutionizing tumor characterization, enabling oncologists to develop tailored treatment plans that are more effective and efficient. By leveraging AI-powered diagnostics, healthcare providers can improve patient outcomes through greater predictability of results. This shift is driving the broader adoption of precision medicine, allowing for targeted therapies that cater to the unique genetic profiles of various cancers. As a result, the market is becoming increasingly focused on innovative, data-driven approaches to solid tumor treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Solid Tumor Therapeutics Market Size by Therapy Types & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Others

Global Solid Tumor Therapeutics Market Size by Cancer Indication & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Others

Global Solid Tumor Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Cancer Research Centers
• Specialty Clinics

Global Solid Tumor Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Types, Cancer Indication, End User)
  • US
  • Canada
• Europe (Therapy Types, Cancer Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Types, Cancer Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Types, Cancer Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Types, Cancer Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gritstone Bio, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Black Diamond Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations